Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
Meet InfiCure Bio at NLSDays April 20-23!
Make sure to book a one-on-one meeting with Dan Holmberg and/or Sofia Mayans, and take the opportunity to discuss the most recent data on the NIF mouse and learn how the model can help in [...]
Meet Dan Holmberg and learn more about the NIF mouse at the 3rd Annual CKD Summit March 2-4!
Dan Holmberg, CSO at InfiCure Bio, will participate at the 3rd Annual Chronic Kidney Disease (CKD) Summit March 2-4, hosted by Hanson Wade. Make sure to take the opportunity to meet with Dan, and learn [...]
Sofia Mayans participates in national pitching event 29th of January 2021
Sofia Mayans, CEO at InfiCure Bio, will participate in the national pitching competition "Hela Sverige Pitchar" by Connect Sverige. InfiCure Bio is one of 5 companies in Life Science/MedTech that will pitch on January 29 [...]
Pressrelease: InfiCure Bio secures US patent and publishes new data in a top scientific journal
https://www.mynewsdesk.com/se/umeaa-biotech-incubator/pressreleases/inficure-bio-secures-us-patent-and-publishes-new-data-in-a-top-scientific-journal-3060618?utm_source=rss&utm_medium=rss&utm_campaign=Alert&utm_content=pressrelease